Marczyńska A, Kulpa J, Leńko J, Augustyn M
Department of Clinical Biochemistry, Oncological Center Branch, Cracow, Poland.
Int Urol Nephrol. 1988;20(2):123-9. doi: 10.1007/BF02550661.
Concurrent measurements of serum TPA and PAP concentrations by double antibody radioimmunoassays were done in 49 patients with prostatic cancer in different clinical stages. The reference group comprised patients suffering from BPH. Positive TPA was found in 32.7% of cancer patients, the lowest percentage in stage A (11.1%) and the highest in stage D (55.6%). The additional value as a diagnostic aid of the TPA test was revealed on the basis of examination of the selected group of patients with not increased PAP. Positive TPA was found in 16.7% of patients: none in stage A, 22.2% in stage B, and 33.3% in stage D. Prostatic cancer remains the most common malignancy of the genitourinary tract. The improvement in the results of treatment involves not only a modernization of treatment modalities but also the introduction of laboratory tests which give the most ample information on the stage of tumour development and improve possibilities to control tumour therapy. Besides the refinement of the determination procedures of specific prostatic markers, prostatic acid phosphatase (PAP), through radio- and enzyme-immunological methods, there is a search for additional markers which might be helpful in diagnosis and follow-up of treatment.
采用双抗体放射免疫分析法对49例不同临床分期的前列腺癌患者同时进行血清组织多肽抗原（TPA）和前列腺酸性磷酸酶（PAP）浓度测定。参照组为良性前列腺增生（BPH）患者。32.7%的癌症患者TPA呈阳性，其中A期最低（11.1%），D期最高（55.6%）。在对PAP未升高的特定患者组进行检查的基础上，揭示了TPA检测作为诊断辅助手段的附加价值。16.7%的患者TPA呈阳性：A期无阳性，B期为22.2%，D期为33.3%。前列腺癌仍然是最常见的泌尿生殖道恶性肿瘤。治疗效果的改善不仅涉及治疗方式的现代化，还包括引入能提供肿瘤发展阶段最丰富信息并提高控制肿瘤治疗可能性的实验室检测。除了通过放射免疫和酶免疫方法完善特异性前列腺标志物前列腺酸性磷酸酶（PAP）的测定程序外，还在寻找有助于诊断和治疗随访的其他标志物。
